Arca
Skip to content
Tools
Tools

SLC9A3: Sodium/hydrogen exchanger 3

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Plasma membrane Na(+)/H(+) antiporter.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on SLC9A3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Tenapanor

Phase 31

  • Squalamine

Phase 20

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      TenapanorApprovedArdelyxSmall moleculeInhibitorSodium/hydrogen exchanger 3 inhibitor6Boxed warning
      SqualaminePhase 3Ohr Pharmaceutical Inc.Small moleculeInhibitorSodium/hydrogen exchanger 3 inhibitor0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
      Tenapanor in Maintenance Hemodialysis PatientsTenapanor—Not yet recruitingHuashan Hospital2026-10-20
      Real-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With HyperphosphatemiaTenapanor—Not yet recruitingPeking University People's Hospital2026-08-20
      A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsTenapanorPhase 3RecruitingArdelyx2026-02-02
      Assessing Tenapanor as a Treatment of CF-related Constipation.TenapanorPhase 3Active, not recruitingMassachusetts General Hospital2025-02-05
      Tenapanor in Synucleinopathy-Related ConstipationTenapanorPhase 2RecruitingCedar Valley Digestive Health Center2024-06-14
      Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CTenapanorPhase 3Enrolling by invitationArdelyx2023-06-15

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Congenital sodium diarrhea
      0.65
      Constipation disorder
      0.50
      Neurodegenerative disease
      0.47
      Age-related macular degeneration
      0.29

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3273, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P48764, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.